Spruce Biosciences, Inc.

Equities

SPRB

US85209E1091

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
0.7669 ^USD	+1.83%		-7.02%	-73.83%

Mar. 15	North American Morning Briefing : Inflation -2-	DJ
Mar. 14	Top Midday Decliners	MT

Spruce Biosciences, Inc. Appoints Libbie Mansell as Chief Regulatory and Quality Officer

April 11, 2022 at 08:00 am EDT

Spruce Biosciences, Inc. announced that Libbie Mansell, Ph.D., M.B.A., R.A.C., has been appointed Chief Regulatory and Quality Officer. Dr. Mansell will be responsible for leading the company's global regulatory affairs and quality strategy.

Latest news about Spruce Biosciences, Inc.

North American Morning Briefing : Inflation -2-	Mar. 15	DJ
Top Midday Decliners	Mar. 14	MT
Sector Update: Health Care Stocks Lower Thursday Afternoon	Mar. 14	MT
HC Wainwright Downgrades Spruce Biosciences to Neutral From Buy	Mar. 14	MT
JMP Securities Adjusts Spruce Biosciences' Price Target to $3 From $8, Maintains Market Outperform Rating	Mar. 14	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	Mar. 14	MT
Leerink Partners Downgrades Spruce Biosciences to Market Perform From Outperform, Adjusts Price Target to $2 From $9	Mar. 14	MT
Guggenheim Downgrades Spruce Biosciences to Neutral From Buy	Mar. 14	MT
Ladenburg Thalmann Downgrades Spruce Biosciences to Neutral From Buy	Mar. 14	MT
Spruce Biosciences Downgraded by RBC to Sector Perform From Outperform, Price Target Cut to $2 From $9, Shares Plunge Pre-Bell; Speculative Risk Kept	Mar. 14	MT
Spruce Biosciences 2023 Loss Narrows; to Cut 21% Workforce After Trial Misses Target; Shares Sink	Mar. 13	MT
Transcript : Spruce Biosciences, Inc., 2023 Earnings Call, Mar 13, 2024	Mar. 13
Spruce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Spruce Biosciences, Inc. Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH	Mar. 13	CI
RBC Lifts Price Target on Spruce Biosciences to $9 From $8, Cites Improved Chances of Congenital Adrenal Hyperplasia Program Success; Outperform, Speculative Risk Kept	Feb. 26	MT
Guggenheim Initiates Spruce Biosciences at Buy Rating With $10 Price Target	Feb. 21	MT
Top Premarket Decliners	Feb. 13	MT
Spruce Biosciences, Inc. Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia	Jan. 22	CI
Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH	Jan. 05	CI
Spruce Biosciences, Inc. Provides Clinical Program Updates and Outlook for 2024	Jan. 04	CI
Spruce Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Spruce Biosciences, Inc. Completes Target Enrollment of CAHmelia-203 Study in Adult Classic Congenital Adrenal Hyperplasia	23-10-18	CI
North American Morning Briefing : Inflation, -2-	23-09-11	DJ
SVB Securities Upgrades Spruce Biosciences to Outperform From Market Perform, Adjusts Price Target to $9 From $3	23-09-08	MT
Oppenheimer Adjusts Spruce Biosciences Price Target to $7 From $8, Maintains Outperform Rating	23-08-18	MT

Chart Spruce Biosciences, Inc.

Duration

Period

More charts

Company Profile

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders with significant unmet medical needs. The Company is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). It is also developing Tildacerfont for females suffering from polycystic ovary syndrome (PCOS). It has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with elevated levels of androstenedione (A4) at baseline. It has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 at baseline focused on glucocorticoid reduction. The Company also investigates tildacerfont for the treatment of classic CAH in children.

Sector

Biotechnology & Medical Research

Calendar

12:00pm - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Spruce Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.7669 USD

Average target price

2.75 USD

Spread / Average Target

+258.59%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SPRUCE BIOSCIENCES, INC.	-73.83%	30.99M
MODERNA, INC.	+44.48%	54.04B
LONZA GROUP AG	+43.57%	41.96B
IQVIA HOLDINGS INC.	-0.86%	41.92B
CELLTRION, INC.	-7.59%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.30%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.83%	19B
BIO-TECHNE CORPORATION	+7.15%	13B
MEDPACE HOLDINGS, INC.	+29.40%	12.28B
UNITED THERAPEUTICS CORPORATION	+25.15%	12.19B

Other Biotechnology & Medical Research